Skip to main content
SpringerLink
Log in

The Treatment of Type 2 Diabetes Mellitus in Youth

Which Therapies?

  • Leading Article
  • Published:
Treatments in Endocrinology

Abstract

Type 2 diabetes mellitus in children and adolescents is becoming an increasingly important public health concern throughout the world. This epidemic is closely associated with the increased prevalence of obesity among youth of all ethnic backgrounds, as increased visceral adipose tissue produces adipokines that increase insulin resistance. Type 2 diabetes represents one arm of the metabolic syndrome, which includes abdominal obesity, disturbed glucose regulation and insulin resistance, dyslipidemia, and hypertension. The treatment of type 2 diabetes and the metabolic syndrome poses a challenge for pediatric endocrinologists. This review provides information regarding diagnosis of type 2 diabetes in children, as well as prevention strategies, such as lifestyle modification and pharmacologie options for weight loss, including metformin, orlistat, and sibutramine. Pharmacologie treatment options, their modes of action, and clinical indications for use are also reviewed. Treatment regimens for youth-onset type 2 diabetes that are discussed include metformin, sulfonylureas, glucosidase inhibitors, thiazolidinediones, glucagon-like peptide-1, and insulin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. American Diabetes Association. T2DM in children and adolescents: consensus conference report. Diabetes Care 2000; 23: 381–9

    Article  Google Scholar 

  2. Decsi T, Molnar D. Insulin resistance syndrome in children: pathophysiology and potential management strategies. Pediatr Drugs 2003; 5(5): 291–9

    Google Scholar 

  3. Weiss R, Dufour S, Taksali SE, et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003 Sep 20; 362(9388): 951–7

    Article  PubMed  CAS  Google Scholar 

  4. Savage PJ, Bennett PH, Senter RG, et al. High prevalence of diabetes in young Pima Indians. Diabetes 1979; 28: 937–42

    Article  PubMed  CAS  Google Scholar 

  5. Pinhas-Hamiel O, Zeitler P. The global spread of T2DM mellitus in children and adolescents. J Pediatr 2005; 146(5): 693–700

    Article  PubMed  Google Scholar 

  6. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. T2DM among North American children and adolescents: an epidemiological review and a public health perspective. J Pediatr 2000; 136: 664–72

    Article  PubMed  CAS  Google Scholar 

  7. Wiegand S, Maikowski U, Blankenstein O, et al. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity: a problem that is no longer restricted to minority groups. Eur J Endocrinol 2004 Aug; 151(2): 199–206

    Article  PubMed  CAS  Google Scholar 

  8. Wabitsch M, Hauner H, Hertrampf M, et al. Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany. Int J Obes Relat Metab Disord 2004 Feb; 28(2): 307–13

    PubMed  CAS  Google Scholar 

  9. Ehtisham S, Hattersley AT, Dunger DB, et al. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 2004 Jun; 89(6): 526–9

    Article  PubMed  CAS  Google Scholar 

  10. Troiano RP, Flegal KM. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics 1998; 101(3 Pt 2): 497–504

    PubMed  CAS  Google Scholar 

  11. Kaur H, Hyder ML, Poston WS. Childhood overweight: an expanding problem. Treat Endocrinol 2003; 2(6): 375–88

    Article  PubMed  Google Scholar 

  12. Robinson TM. Reducing children’s television viewing to prevent obesity: a randomized controlled trial. JAMA 1999; 82: 1561–7

    Article  Google Scholar 

  13. Cugnet C, Thivolet C. Classification of diabetes in young adults: new concepts for an old disease. Diabetes Metab 2005 Dec; 31(6): 595–8

    Article  PubMed  CAS  Google Scholar 

  14. Lindgren CM, Hirschhorn JN. The genetics of type 2 diabetes. Endocrinologist 2001; 11: 178–87

    Article  Google Scholar 

  15. Winter WE. Molecular and biochemical analysis of the MODY syndromes. Pediatr Diabetes 2000; 1:88–117

    Article  PubMed  CAS  Google Scholar 

  16. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26: 163–75

    Article  PubMed  CAS  Google Scholar 

  17. Baier LJ, Permana PA, Yang X, et al. A calpain 10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000; 106: R69–73

    Article  PubMed  CAS  Google Scholar 

  18. Jiang X, Srinivasan SR, Radhakrishnamurthy B, et al. Racial (black-white) differences in insulin secretion and clearance in adolescents: the Bogalusa Heart Study. Pediatrics 1996; 97(3): 357–60

    PubMed  CAS  Google Scholar 

  19. Webster-Gandy J, Warren J, Henry CJ. Sexual dimorphism in fat patterning in a sample of 5 to 7-year-old children in Oxford. Int J Food Sci Nutr 2003; 54(6): 467–71

    Article  PubMed  CAS  Google Scholar 

  20. Danadian K, Balasekaran G, Lewy V, et al. Insulin sensitivity in African-American children with and without a family history of type 2 diabetes. Diabetes Care 1999; 22: 1325–9

    Article  PubMed  CAS  Google Scholar 

  21. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of T2DM mellitus: results of a 25 year follow-up study. Lancet 1992; 340: 925–9

    Article  PubMed  CAS  Google Scholar 

  22. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802–10

    Article  PubMed  CAS  Google Scholar 

  23. Caprio S. Relationship between abdominal visceral fat and metabolic risk factors in obese adolescents. Am J Hum Biol 1999; 11: 259–66

    Article  PubMed  Google Scholar 

  24. Freedman DS, Khan LK, Dietz WH, et al. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 2001; 108:712–8

    Article  PubMed  CAS  Google Scholar 

  25. Weiss R, Taksali SE, Dufour S, et al. The ‘obese insulin-sensitive’ adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab 2005 Jun; 90(6): 3731–7

    Article  PubMed  CAS  Google Scholar 

  26. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004 Jun 17; 350(25): 2549–57

    Article  PubMed  CAS  Google Scholar 

  27. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003; 3: 293–8

    Article  PubMed  Google Scholar 

  28. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236–40

    Article  PubMed  CAS  Google Scholar 

  29. Huypens P, Moens K, Heimberg H, et al. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 2005 Jul 29;77(ll): 1273–82

    Article  PubMed  CAS  Google Scholar 

  30. O’Rahilly S, Turner RC, Mathew D. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 1988; 318: 1225–30

    Article  PubMed  Google Scholar 

  31. Zuhri-Yafi MI, Brosnan PG, Hardin DS. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2002; 15Suppl. 1: 541–6

    PubMed  Google Scholar 

  32. Morales A, Rosenbloom AL. Death at the onset of type 2 diabetes (T2DM) in African-American youth. J Pediatr 2004; 144: 270–3

    Article  PubMed  Google Scholar 

  33. Rosenbloom AL. Obesity, insulin resistance, beta cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 2003; 26: 2954–6

    Article  PubMed  Google Scholar 

  34. Turner R, Stratton I, Horton V, et al. Autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288–93

    Article  PubMed  CAS  Google Scholar 

  35. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002; 958: 112–6

    Article  PubMed  Google Scholar 

  36. Pontiroli AE. Type 2 diabetes mellitus is becoming the most common type of diabetes in school children. Acta Diabetol 2004 Sep; 41(3): 85–90

    Article  PubMed  CAS  Google Scholar 

  37. de Ferranti SD, Gauvreau K, Ludwig DS, et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004 Oct 19; 110(16): 2494–7

    Article  Google Scholar 

  38. American Diabetes Association Consensus Development Conference on Insulin Resistance. Diabetes Care 1998; 21: 310-14

    Google Scholar 

  39. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  40. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

    Article  Google Scholar 

  41. Miller JL, Silverstein JH. The management of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2005 Feb; 18(2): 111–23

    Article  PubMed  Google Scholar 

  42. Franz MJ, Splett PL, Monk A, et al. Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc 1995; 95: 1018–24

    Article  PubMed  CAS  Google Scholar 

  43. Bergenstal RM, Kendall DM, Franz MJ, et al. Management of type 2 diabetes: a systematic approach to meeting the standards of care: II. Oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th ed. Philadelphia (PA): WB Saunders Co, 2001: 821–35

    Google Scholar 

  44. Apovian CM. Sugar-sweetened soft drinks, obesity, and type 2 diabetes. JAMA 2004; 292: 927–34, 978-9

    Article  Google Scholar 

  45. Miller WC. How effective are traditional dietary and exercise interventions for weight loss? Med Sci Sports Exerc 1999; 31: 1129–34

    Article  PubMed  CAS  Google Scholar 

  46. Leung WY, Neil Thomas G, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58–80

    Article  PubMed  CAS  Google Scholar 

  47. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873–83

    Article  PubMed  CAS  Google Scholar 

  48. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107(4): E55

    Article  PubMed  CAS  Google Scholar 

  49. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33

    Article  PubMed  CAS  Google Scholar 

  50. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–8

    Article  PubMed  CAS  Google Scholar 

  51. Esposito K, Giugliano D. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 2005; 366: 367–8, author reply 369-70

    Article  PubMed  Google Scholar 

  52. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541–9

    Article  PubMed  CAS  Google Scholar 

  53. Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2005 Nov; 6(14): 2419–27

    Article  PubMed  CAS  Google Scholar 

  54. Lebovitz HE. Insulin secretagogues, old and new. Diabetes Reviews 1999; 7: 139–52

    Google Scholar 

  55. Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89–94

    Article  PubMed  CAS  Google Scholar 

  56. Chiasson J, Josse R, Hunt J, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928–35

    PubMed  CAS  Google Scholar 

  57. Olefsky JM, Saltiel AR. PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab 2000; 11: 362–7

    Article  PubMed  CAS  Google Scholar 

  58. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin treated patients with type 2 diabetes. N Engl J Med 1998; 338: 861–6

    Article  PubMed  CAS  Google Scholar 

  59. Law RE, Goetze S, XI X-P, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311–8

    Article  PubMed  CAS  Google Scholar 

  60. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003 Jan; 52(1): 102–10

    Article  PubMed  CAS  Google Scholar 

  61. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemie control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004 Nov; 27(11): 2597–602

    Article  PubMed  CAS  Google Scholar 

  62. Glaser B, Cerasi E. Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999; 1: 67–74

    Article  PubMed  CAS  Google Scholar 

  63. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330–6

    Article  PubMed  CAS  Google Scholar 

  64. Huvers F. Long acting insulin analogs: possibly more stable glucose regulation. Ned Tijdschr Geneeskd 2004 Aug 21; 148(34): 1674–8

    PubMed  CAS  Google Scholar 

  65. Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes in children and adolescents. J Ped Endocrinol Metab 2000; 13(Suppl. 6): 1403–9

    Google Scholar 

  66. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, et al. Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 2003; 27: 1359–64

    Article  PubMed  CAS  Google Scholar 

  67. Leon DD, Crutchlow MF, Ham JY, et al. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2006; 38(5–6): 845–59

    Article  PubMed  Google Scholar 

  68. Aston-Mourney K, Proietto J, Andrikopoulos S. Investigational agents that protect pancreatic islet beta-cells from failure. Expert Opin Investig Drugs 2005; 14: 1241–50

    Article  PubMed  CAS  Google Scholar 

  69. Bergenstal RM, Kendall DM, Franz MJ, et al. Management of type 2 diabetes: a systematic approach to meeting the standards of care: II. Oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th ed. Philadelphia (PA): WB Saunders Co, 2001: 821–35

    Google Scholar 

  70. National Heart, Lung, and Blood Institute. Report of the Second Task Force on Blood Pressure Control in Children: 1987. J Pediatr 1987; 79: 1–25

    Google Scholar 

  71. Kavgaci H, Sahin A, Onder Ersoz H, et al. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract 2002 Oct; 58(1): 19–25

    Article  PubMed  CAS  Google Scholar 

  72. Adler AI. Treating high blood pressure in diabetes: the evidence. Semin Vasc Med 2002; 2: 127–37

    Article  PubMed  Google Scholar 

  73. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999; 59: 2661–7

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the Lawson Wilkins Pediatric Endocrine Society for providing funding that supported the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology, University of Florida, Box 100296, JHMHC, Gainesville, Florida, 32610-0296, USA

    Jennifer L. Miller & Janet H. Silverstein

Authors
  1. Jennifer L. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet H. Silverstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. Miller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, J.L., Silverstein, J.H. The Treatment of Type 2 Diabetes Mellitus in Youth. Mol Diag Ther 5, 201–210 (2006). https://doi.org/10.2165/00024677-200605040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200605040-00001

Keywords

Search

Navigation